Key Points
- Clear U.S. retail context. Vapesourcing lists RELX Creator Pro 15K as “Coming Soon” and shows U.S. warehouse shipping options.
- Official path unconfirmed. RELX’s global official store does not currently support U.S. orders, and the product’s PMTA / sPMTA status has not been publicly disclosed.
- FDA policy is reshaping risk tiers. Reuters reported that about 100–200 qualifying unauthorized products could immediately benefit, but enforcement discretion is not an MGO.
- A more restrained specification set. The product uses 3% nicotine, 15K puffs and 10ml total capacity, unlike common U.S. disposables built around 5% nicotine, 20K–25K puffs and larger e-liquid volumes.
- A structure with European compliance traces. Its 2ml pod plus 8ml refill container resembles the U.K./EU “2ml + refill container” format, though 3% nicotine does not match U.K./EU nicotine limits.
2Firsts
June 11, 2026
U.S.-facing and cross-border vape retailer Vapesourcing has listed the “RELX Creator Pro 15K Disposable Vape Kit 3%” as “Coming Soon,” with U.S. warehouse shipping options shown on the product page. The listing does not show that RELX has entered the U.S. market through official channels, nor does it indicate FDA marketing authorization. But following the FDA’s updated enforcement priorities for certain unauthorized ENDS and nicotine pouch products, the third-party pre-listing offers a new signal for how Chinese brand-led ENDS companies may assess the U.S. regulatory window.
A Third-Party Page With U.S. Retail Context
Vapesourcing is a vape e-commerce platform serving U.S. and cross-border consumers. Its website includes a “US Store” entrance and displays shipping messages such as “Free Shipping on $95+ From USA Warehouse.” On the RELX Creator Pro 15K product page, the platform lists multiple warehouse and shipping options. “U.S.A Warehouse” is described as shipping from the United States, only to the United States, with a 3–10 business day delivery time. “US-02 Warehouse” is also described as shipping from the United States, only to the United States, with a 5–10 business day delivery window.
That means the page is not merely a global product-information page. It appears within a commerce environment that supports U.S. online orders and maintains U.S. warehouse logistics. As of 2Firsts’ review, however, the product remains marked “Coming Soon” and does not appear to be available for purchase.
The Vapesourcing page describes Creator Pro 15K as offering about 15,000 puffs, 3% nicotine and 10ml total capacity, consisting of a 2ml prefilled pod and an 8ml refill container. The device has an 800mAh battery, Type-C charging, and two power modes: Normal Mode at 15W and Boost Mode at 25W.
RELX’s official global site also has a Creator Pro Device page, describing features including a smart display, adjustable airflow, Type-C charging, an 800mAh battery, and 15W / 25W power modes. But the official global site does not currently show support for U.S. ordering.
The Vapesourcing page therefore points to a third-party pre-listing rather than an official U.S. launch by RELX. It shows that a third-party retailer has created a U.S.-visible online shelf and search entry for the product, but it does not show that the product has entered active U.S. sales.
What the FDA’s Lower-Priority Enforcement Window Changed
The FDA’s May enforcement-priority guidance has introduced a new layer of risk differentiation into the unauthorized ENDS market.
Previously, the market’s baseline view of unauthorized vape products was relatively simple: without FDA marketing authorization, a product carried high enforcement risk. The new guidance does not change the statutory PMTA threshold. But it does change how companies and retailers assess near-term enforcement risk. Unauthorized products are no longer being treated by the market as a single risk category. Whether a product has an application basis, has entered FDA review, and includes sufficient scientific evidence now matters more to commercial decisions.
Reuters previously reported that the FDA policy shift could make major tobacco companies the key beneficiaries. Citing current and former Trump administration officials, Reuters reported that the FDA would exercise enforcement discretion for certain unauthorized ENDS and nicotine pouch products that meet specific criteria. One official said about 100–200 products could benefit immediately, with more potentially entering the market in the coming weeks or months. The report also noted concerns from public-health advocates over youth-use risks.
The core of the policy shift is not that unauthorized products can simply be sold. It is that the FDA is ranking unauthorized products by enforcement priority. Under the guidance, products that may fall within the lower-priority category must meet conditions: they must have submitted a PMTA or related marketing application, the application must be pending, and it must have been accepted and filed by the FDA. For non-tobacco-flavored ENDS, applications must also contain sufficient data for the agency to assess whether the product is appropriate for the protection of public health, or APPH.
That creates a new risk gradient in the U.S. unauthorized ENDS market. Products with applications already in the FDA review pipeline and a scientific data package may face lower near-term enforcement risk. Products without an application basis, products that appear designed to evade regulation, products with safety concerns, or products with strong youth appeal may remain higher-priority enforcement targets.
For companies and retailers, the change affects shelf decisions. Application status, product specifications, data quality, age verification, child-resistant packaging and marketing controls are all becoming variables in how the market assesses short-term enforcement exposure.
That is why the Creator Pro 15K page on Vapesourcing is notable. The central question is not whether the product has officially entered the U.S. market. It is whether, after the FDA opened a lower-priority enforcement window for certain qualifying products, third-party channels are reassessing the risk-reward profile of placing selected global ENDS products on U.S.-visible shelves.
Why This Signal Is Especially Sensitive for Chinese Brands
A senior industry professional familiar with the globalization strategies of Chinese vape companies told 2Firsts that if the FDA policy creates a limited enforcement buffer for qualifying unauthorized products, the Chinese companies best positioned to test that window may not be those relying on illicit-trade channels in the U.S. market, nor manufacturers focused mainly on OEM production.
Instead, the person said, companies such as RELX — with a public-company background, brand-management capabilities and international business infrastructure — may have stronger incentives to explore a long-term compliance route.
The person added that such companies would be more likely to view the U.S. as part of a long-term regulatory strategy rather than a short-term gray-market sales opportunity. Whether any product can actually fall within FDA’s lower-priority enforcement scope, however, still depends on application status, scientific evidence and risk controls.
Unlike many Chinese vape firms focused on manufacturing, OEM production or channel trade, RELX is closer to a brand-led ENDS company. It is also among the few China-linked vape companies with public-market exposure. U.S.-related activity would involve not just product sales, but FDA compliance, investor relations, brand reputation and global strategy.
Over the past several years, RELX has been shifting its business from a China-dependent model toward a more diversified international footprint. The U.S. remains difficult to access through official channels, but it is still too large and strategically important to ignore.
At the same time, RELX’s brand position and listed-company status make direct participation in the U.S. gray ENDS market difficult without a clear MGO or stable regulatory path. In a market heavily populated by unauthorized products, any official sales move could amplify regulatory, reputational and capital-market risks.
That explains the significance of the current mismatch: RELX’s official global site does not support U.S. orders, while a third-party U.S.-facing retailer has created a Coming Soon page. The listing is not enough to establish brand intent. But it does show that U.S. channel players may be reassessing the regulatory risk of bringing Chinese brand-led ENDS products onto U.S.-visible shelves.
Does Creator Pro 15K Have the Specification Basis of a “Window Product”?
The public specifications of Creator Pro 15K are not enough to define it as a low-risk product. It remains a nicotine-containing ENDS product, and the listed flavors include fruit, tea and cooling profiles. Under the U.S. PMTA system, non-tobacco-flavored ENDS products must still show that potential benefits for adult smokers outweigh youth-use risks.
Still, the product does not fully replicate the most aggressive U.S. disposable-vape formula. The U.S. disposable category is commonly built around 20,000–25,000 puffs or more, 16ml–20ml e-liquid capacity, 5% / 50mg nicotine salts, rechargeable 800mAh-class batteries, and high-intensity features such as pulse or boost modes.
By comparison, the Vapesourcing page lists RELX Creator Pro 15K with about 15,000 puffs, 3% nicotine, 10ml total capacity, an 800mAh battery, 15W / 25W dual power modes, and a 2ml prefilled pod plus 8ml refill container. Its battery capacity and peak output are not low. The difference lies mainly in a lower nicotine level, smaller total capacity, and a product position that does not fully follow the 20K–25K-plus puff-count race.
The 2ml pod plus 8ml refill container structure is also notable. It closely resembles the “2ml pod + refill container” big-puff format that has emerged in the U.K. and European markets. Under U.K. and EU TPD / TPR rules, e-cigarette tanks or pods are generally limited to 2ml, while nicotine-containing refill containers are generally limited to 10ml. In response, the U.K. market has seen a wave of so-called TPD-compliant big-puff kits that use a 2ml pod and refill-container or auto-refill structure to meet the 2ml tank limit while offering higher puff counts than traditional 2ml disposables.
In that sense, Creator Pro looks less like the one-piece, 16ml–20ml disposable format common in the U.S. market, and more like a European-style structure: a 2ml pod as the vaporization unit, supported by a separate refill container for additional e-liquid capacity. That gives the product a more modular and system-based profile than the one-piece, ultra-high-capacity disposable format.
The product should not, however, be described as U.K. or EU compliant. Vapesourcing lists its nicotine strength at 3%, above the U.K./EU limit of 20mg/ml, or roughly 2%. Creator Pro therefore appears to combine a European-style structure with a nicotine level more aligned with U.S. consumer expectations.
Put simply, the product uses a European structural language to tell a U.S. big-puff story. That structure does not automatically translate into an advantage under the U.S. PMTA system, but compared with the most aggressive high-capacity U.S. disposables, the specification set gives the product a different positioning.
The Missing Piece: Application Status and Scientific Evidence
Whether RELX Creator Pro 15K could fall within the FDA’s lower-priority enforcement framework depends on application status and scientific evidence, not on public-facing product specifications alone.
RELX has not publicly disclosed whether Creator Pro 15K, or its related pod, refill container or nicotine formulation, has been submitted through a PMTA or sPMTA and received accepted-and-filed status. Because the FDA generally does not fully disclose the status and progress of products under review, outside observers cannot confirm from public information alone whether the product is in the agency’s review pipeline.
A PMTA expert familiar with the process told 2Firsts that, based solely on the publicly available specifications, Creator Pro 15K may have a better chance of entering the FDA filing stage than some high-volume, unauthorized big-puff disposable formats currently active in the U.S. market. The expert cited the product’s 3% nicotine level, 10ml total capacity, 15K puff count, and 2ml pod plus 8ml refill-container design as factors that differ from the 20K–25K-plus, 16ml–20ml, 5% nicotine and high-intensity product path often seen in the U.S. disposable segment.
The expert also stressed that filing is not the same as an MGO, and does not mean a product will ultimately meet the APPH standard. During substantive review, the FDA would still examine toxicology, aerosol chemistry, behavioral impact, youth appeal, marketing controls, age verification and product safety.
The information currently available supports one conclusion: Creator Pro 15K has a potential compliance-oriented positioning, but whether it has the application status required for lower-priority enforcement cannot be confirmed from public information. Without sufficient APPH evidence and verifiable youth-risk controls, product-specification differences cannot become a regulatory safe harbor.
Three developments will determine whether this listing becomes more than a signal: whether the Vapesourcing page changes from Coming Soon to In Stock; whether RELX or related entities publicly disclose PMTA / sPMTA accepted-and-filed status; and whether major U.S. vape retailers begin listing Creator Pro or the broader Creator series.
In the U.S. ENDS market, competition may be shifting from pure supply-chain speed and channel expansion toward regulatory risk pricing. For a brand-led public company such as RELX, the key question is not whether it can move quickly onto U.S. shelves, but whether it can build a regulatory position distinct from the high-risk unauthorized products that are most likely to draw enforcement.
（Cover Image：RELX’s official global）
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
